Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical study of IMC001 for the treatment of EpCAM-positive advanced gastrointestinal tumors in United state.

Next Previous
Trial Profile

Clinical study of IMC001 for the treatment of EpCAM-positive advanced gastrointestinal tumors in United state.

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMC 001 Suzhou Immunofoco Biotechnology (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Solid tumours
  • Focus Adverse reactions

Most Recent Events

  • 13 Jun 2024 New trial record
  • 22 Feb 2024 According to Immunofoco media release, the company received an Approval of IND Applications by the U.S. FDA for IMC001,the First EpCAM CAR-T Targeted at Advanced Solid Tumors.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top